Janssen-Cilag International has reported positive results from a pooled analysis that includes Phase ll and lll studies of imbruvica (ibrutinib) in patients with relapsed/refractory (r/r) mantle cell lymphoma (MCL).

The analysis also includes extended follow-up data of 87 patients enrolled across the two studies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The data also demonstrated that patients treated with imbruvica earlier or at first relapse experienced improved clinical results in terms of both efficacy and tolerability.

As part of the long-term open-label extension study, 83 of the total subjects were treated with ibrutinib for three or more years, while 40 patients were treated with ibrutinib for four or more years.

After following them up for 3.5 years, the overall median progression-free survival (PFS) was 13 months and 33.6 months in patients with one prior line of therapy.

The median PFS in patients who achieved complete response (CR) was 46.2 months and the duration of response in these patients was 55.7 months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“New onset adverse events decrease over time and are generally less common when patients are treated earlier.”

Results also found that the patients with favourable baseline disease characteristics were more likely to remain on ibrutinib for more than three years.

In addition, 53%, 45% and 37% of patients were alive at two, three, and five years respectively, and the median overall survival (OS) was 26.7 months.

Plymouth University Medical School Haematology professor and the pooled analysis lead investigator Simon Rule said: “Data from this large clinical trial dataset with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma.

“Long-term follow-up for ibrutinib demonstrates, that in addition to efficacy, new onset adverse events decrease over time and are generally less common when patients are treated earlier.”

Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, which is designed to work by forming a strong covalent bond with BTK to block the transmission of cell survival signals within the malignant B-cells.